<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="24793">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02784002</url>
  </required_header>
  <id_info>
    <org_study_id>SMT19969/C003</org_study_id>
    <nct_id>NCT02784002</nct_id>
  </id_info>
  <brief_title>A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI)</brief_title>
  <official_title>A Phase II, Randomized, Open-Label, Active-Controlled Clinical Study to Investigate the Safety and Efficacy of SMT19969 (200mg BID) for 10 Days Compared With Fidaxomicin (200 mg BID) for 10 Days for the Treatment of Clostridium Difficile Infection (CDI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Summit Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Summit Therapeutics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to evaluate the safety and effectiveness of
      Ridinilazole (SMT19969) in treating C. difficile Infection (CDI).
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of treatment emergent adverse events (AEs) and serious adverse events (SAEs) to evaluate safety and tolerability</measure>
    <time_frame>30 days post End of Therapy</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the pharmacokinetics of SMT19969 in patients with CDI by measuring the plasma, urine and fecal concentrations of SMT19969</measure>
    <time_frame>12 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the qualitative and quantitative effect on the bowel flora of each subject using 16S ribosomal RNA sequencing, metagenomics and bioinformatic techniques</measure>
    <time_frame>40 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure clinical cure rates at the Test of Cure (TOC) visit</measure>
    <time_frame>12 days</time_frame>
    <description>Investigator assessed clinical response at the TOC visit (on day 12) with clinical cure defined as the resolution of diarrhoea (â‰¤ 3 Unformed Bowel Movements (UBMs) per day) while on treatment that is maintained until the TOC visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure sustained clinical response (SCR) rates</measure>
    <time_frame>40 days</time_frame>
    <description>SCR is defined as clinical cure at TOC and no recurrence of CDI within 30 days post end of treatment (EOT).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Clostridium Difficile Infection</condition>
  <arm_group>
    <arm_group_label>Ridinilazole (SMT19969)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg capsule of Ridinilazole (SMT19969) twice a day for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fidaxomicin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>200 mg tablet of Fidaxomicin twice a day for 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ridinilazole</intervention_name>
    <arm_group_label>Ridinilazole (SMT19969)</arm_group_label>
    <other_name>SMT19969</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fidaxomicin</intervention_name>
    <arm_group_label>Fidaxomicin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed Consent

          -  Clinical diagnosis of CDI plus laboratory diagnostic test

          -  No more than 30 hours antimicrobial treatment for current CDI episode

          -  Female subjects of childbearing potential must use adequate contraception

        Exclusion Criteria:

          -  Life-threatening or fulminant CDI

          -  Subjects with 2 or more episodes of CDI in the previous year

          -  Females who are pregnant or breastfeeding

          -  History of inflammatory bowel disease

          -  Co-administration of potent P-glycoprotein inhibitors

          -  Participation in other Clinical research studies within one month of screening

          -  Subjects that the Investigator feels are inappropriate for the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Summit Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Laguna Hills</name>
      <address>
        <city>Laguna Hills</city>
        <state>California</state>
        <zip>92653</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ventura</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Idaho</name>
      <address>
        <city>Idaho</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Butte</name>
      <address>
        <city>Butte</city>
        <state>Montana</state>
        <zip>59701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Jersey</name>
      <address>
        <city>New Jersey</city>
        <state>New Jersey</state>
        <zip>08244</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liberec</name>
      <address>
        <city>Liberec</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pardubice</name>
      <address>
        <city>Pardubice</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praha</name>
      <address>
        <city>Praha</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zlin</name>
      <address>
        <city>Zlin</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leeds</name>
      <address>
        <city>Leeds</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liverpool</name>
      <address>
        <city>Liverpool</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Manchester</name>
      <address>
        <city>Manchester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Newcastle Upon Tyne</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oxford</name>
      <address>
        <city>Oxford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wigan</name>
      <address>
        <city>Wigan</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <lastchanged_date>August 2, 2016</lastchanged_date>
  <firstreceived_date>May 16, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
